20020203
 Business Brief -- Novartis AG: FDA Gives a Green Light To Gleevec Cancer Drug   The Wall Street Journal,  Feb 4, 2002  Novartis AG's remarkable cancer drug, Gleevec, received approval from the U.S. Food and Drug Administration to treat patients suffering from inoperable or metastatic malignant gastrointestinal stromal tumors.   
